Patents Assigned to ALTIMMUNE UK LIMITED
-
Patent number: 11918645Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.Type: GrantFiled: July 9, 2022Date of Patent: March 5, 2024Assignee: Altimmune UK LimitedInventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
-
Publication number: 20230090379Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.Type: ApplicationFiled: July 9, 2022Publication date: March 23, 2023Applicant: Altimmune UK LimitedInventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
-
Publication number: 20220073446Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.Type: ApplicationFiled: July 19, 2021Publication date: March 10, 2022Applicant: Altimmune UK LimitedInventors: Dominique Bonnet, Carlton B Brown, Bertrand V. Georges, Philip J Sizer
-
Publication number: 20210316000Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.Type: ApplicationFiled: November 11, 2018Publication date: October 14, 2021Applicant: Altimmune UK LimitedInventors: Dominique Bonnet, Carlton Brown, Bertrand Georges, Philip Sizer
-
Publication number: 20210038710Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.Type: ApplicationFiled: June 23, 2020Publication date: February 11, 2021Applicant: Altimmune UK LimitedInventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
-
Patent number: 10849984Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.Type: GrantFiled: October 7, 2019Date of Patent: December 1, 2020Assignee: Altimmune UK LimitedInventor: Bertrand Georges
-
Publication number: 20200316211Abstract: Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.Type: ApplicationFiled: April 1, 2020Publication date: October 8, 2020Applicant: Altimmune UK LimitedInventors: Bertrand Georges, Scot Roberts, Isabelle Peguillet
-
Patent number: 10729759Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.Type: GrantFiled: July 23, 2015Date of Patent: August 4, 2020Assignee: Altimmune UK LimitedInventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
-
Patent number: 10300132Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.Type: GrantFiled: December 20, 2013Date of Patent: May 28, 2019Assignee: Altimmune UK LimitedInventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
-
Publication number: 20190142951Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.Type: ApplicationFiled: November 11, 2018Publication date: May 16, 2019Applicant: Altimmune UK LimitedInventors: Dominique Bonnet, Carlton Brown, Bertrand Georges, Philip Sizer
-
Patent number: 9962453Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.Type: GrantFiled: December 2, 2014Date of Patent: May 8, 2018Assignee: ALTIMMUNE UK LIMITEDInventor: Bertrand Georges
-
Patent number: 9446143Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.Type: GrantFiled: December 23, 2013Date of Patent: September 20, 2016Assignee: ALTIMMUNE UK LIMITEDInventors: Dominique Bonnet, Carlton B. Brown, Bertrand Victor Gilbert Georges, Philip J. Sizer